Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Thilo Welsch

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2314-0757; OpenAlex author ID A5091124243. Sources: OpenAlex.

Their work

Papers
29 (first author 0, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
117
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 2 papers · 2016: 3 papers · 2017: 4 papers · 2018: 3 papers · 2019: 3 papers · 2020: 4 papers · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: none · 2025: none · 2026: 2 papers

Papers 29

  1. Concordance between GPT-4 and a multidisciplinary tumor board in pancreatic cancer: A prospective pilot study. Last author DOI 10.1007/s00423-026-04242-9↗
  2. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  3. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment. Co-author DOI 10.1002/path.5906↗
  4. Label-free differentiation of human pancreatic cancer, pancreatitis, and normal pancreatic tissue by molecular spectroscopy. Co-author DOI 10.1117/1.jbo.27.7.075001↗
  5. Impact of resection margin status on survival in advanced N stage pancreatic cancer - a multi-institutional analysis. Last author DOI 10.1007/s00423-021-02138-4↗
  6. Gamma-delta T cells stimulate IL-6 production by pancreatic stellate cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-020-03367-8↗
  7. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels. Co-author DOI 10.1038/s41388-020-1186-7↗
  8. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗
  9. PD-1 Expression by Lymph Node and Intratumoral Regulatory T Cells Is Associated with Lymph Node Metastasis in Pancreatic Cancer. Co-author DOI 10.3390/cancers12102756↗
  10. Development of a Class Prediction Model to Discriminate Pancreatic Ductal Adenocarcinoma from Pancreatic Neuroendocrine Tumor by MALDI Mass Spectrometry Imagin… Co-author DOI 10.1002/prca.201800046↗
  11. CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids. Last author DOI 10.1155/2019/1024614↗
  12. Erratum to "CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids". Last author DOI 10.1155/2019/9209764↗
  13. [Early stage pancreatic cancer]. Last author DOI 10.1007/s00104-017-0569-y↗
  14. Validation of prognostic risk scores for patients undergoing resection for pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.05.005↗
  15. The "T" now Matters: The Eighth Edition of the Union for International Cancer Control Classification of Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002531↗
  16. Modulation of RAB5A early endosome trafficking in response to KRas mediated macropinocytic fluxes in pancreatic cancer cells. Last author DOI 10.1016/j.bbrc.2017.08.157↗
  17. Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection. Last author DOI 10.1038/s41598-017-08165-w↗
  18. Impact of Intraoperative Re-resection to Achieve R0 Status on Survival in Patients With Pancreatic Cancer: A Single-center Experience With 483 Patients. Co-author DOI 10.1097/sla.0000000000001808↗
  19. Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer. Co-author DOI 10.1186/s12885-017-3225-5↗
  20. Top-down approach to the superior mesenteric artery and the mesopancreas during pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1002/jso.24204↗
  21. Impact of Portal Vein Involvement from Pancreatic Cancer on Metastatic Pattern After Surgical Resection. Last author DOI 10.1245/s10434-016-5515-6↗
  22. Role of TFEB-driven autophagy regulation in pancreatic cancer treatment. Last author DOI 10.3892/ijo.2016.3505↗
  23. Salinomycin inhibits growth of pancreatic cancer and cancer cell migration by disruption of actin stress fiber integrity. Last author DOI 10.1016/j.canlet.2014.12.037↗
  24. CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/cdd.2014.217↗
  25. Impact of preoperative diabetes on long-term survival after curative resection of pancreatic adenocarcinoma: a systematic review and meta-analysis. Last author DOI 10.1245/s10434-013-3415-6↗
  26. Expression of galectin-3 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12253-011-9444-1↗
  27. The need for extended intensive care after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-010-0629-y↗
  28. Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer. Co-author DOI 10.1186/1471-2407-11-275↗
  29. Prognostic significance of erythropoietin in pancreatic adenocarcinoma. Co-author DOI 10.1371/journal.pone.0023151↗

Closest collaborators

The 25 strongest of 117 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jürgen Weitz · 17 shared papers, 2011–2022 · strength 1.50
  2. Marius Distler · 12 shared papers, 2016–2022 · strength 1.06
  3. Christoph Kahlert · 6 shared papers, 2011–2022 · strength 0.56
  4. Christian Teske · 5 shared papers, 2015–2022 · strength 0.50
  5. Thilo Hackert · 2 shared papers, 2026 · strength 0.45
  6. Faik Güntac Uzunoglu · 2 shared papers, 2026 · strength 0.45
  7. Adrian M. Seifert · 4 shared papers, 2018–2020 · strength 0.40
  8. Christoph Reißfelder · 5 shared papers, 2017–2020 · strength 0.40
  9. Alexander Hennig · 4 shared papers, 2019–2022 · strength 0.35
  10. Daniel E. Stange · 4 shared papers, 2019–2022 · strength 0.35
  11. Max Heiduk · 3 shared papers, 2020 · strength 0.30
  12. Lena Seifert · 3 shared papers, 2020 · strength 0.30
  13. Anna Nießen · 1 shared paper, 2026 · strength 0.27
  14. Marianne Sinn · 1 shared paper, 2026 · strength 0.27
  15. Fiete Gehrisch · 1 shared paper, 2026 · strength 0.27
  16. Nuh N. Rahbari · 4 shared papers, 2014–2018 · strength 0.26
  17. Kristin Werner · 3 shared papers, 2016–2019 · strength 0.24
  18. T Sugawara · 1 shared paper, 2026 · strength 0.18
  19. Freek D. Daams · 1 shared paper, 2026 · strength 0.18
  20. Daniel Brock Hewitt · 1 shared paper, 2026 · strength 0.18
  21. Ingmar Florin Rompen · 1 shared paper, 2026 · strength 0.18
  22. Izaak Quintus Molenaar · 1 shared paper, 2026 · strength 0.18
  23. Leonard W. F. Seelen · 1 shared paper, 2026 · strength 0.18
  24. Oskar Franklin · 1 shared paper, 2026 · strength 0.18
  25. Patrik Larsson · 1 shared paper, 2026 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.